Understand the source comparison
Do Peptides Help with Erectile Dysfunction: Comparison
PT-141 (Bremelanotide) Melanocortin-4 receptor agonist; activates hypothalamic arousal circuits 54% in PDE5 inhibitor non-responders (JSOM 2020) Psychogenic ED, neurogenic ED, SSRI-induced dysfunction Nausea in 40% of users; ineffective in severe vascular ED I
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- PT-141 (Bremelanotide)
- Melanocortin-4 receptor agonist; activates hypothalamic arousal circuits
- 54% in PDE5 inhibitor non-responders (JSOM 2020)
- Psychogenic ED, neurogenic ED, SSRI-induced dysfunction
- Nausea in 40% of users; ineffective in severe vascular ED
- Intranasal Oxytocin
- Parasympathetic stimulation via sacral spinal projections; amygdala anxiolysis
- 58% improvement in performance anxiety ED (UCSF 2018)
- Performance anxiety, stress-related ED
- Short duration (90 minutes); minimal effect in organic ED
- Kisspeptin
- Hypothalamic GnRH stimulation; increases testosterone signaling
- 42% improvement in hypogonadism-related ED (Imperial College 2019)
- Low testosterone with intact vasculature
- Requires baseline testosterone <300 ng/dL to show benefit
- Melanotan II
- Non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R)
- Insufficient RCT data; case reports show 30–50% subjective improvement
- Psychogenic ED (unvalidated)
- Systemic melanocortin activation causes hyperpigmentation, hypertension
- Professional Assessment
- PT-141 is the only peptide with Phase 3 trial validation for erectile dysfunction. Oxytocin shows promise in anxiety-driven cases. Melanotan II lacks standardized dosing and safety data. Informal use common but clinical evidence weak. All peptides fail in vascular-origin ED.